Similar Tracks
Common CMC (Quality) Issues and How to Avoid Them Part II (13of16) Generic Drugs Forum 2020
U.S. Food and Drug Administration
Overview of Post-approval Chemistry, Manufacture, and Controls (CMC) Changes to an NDA - REdI 2020
U.S. Food and Drug Administration
Clinical Pharmacology Considerations for Radiolabeled Mass Balance Studies
U.S. Food and Drug Administration
M13A: Bioequivalence for Immediate-Release Solid Oral Dosage Forms - Implementing the Final Guidance
U.S. Food and Drug Administration
Chemistry, Manufacturing Controls (CMC) in an Investigational New Drug (IND) (7/14) REdI 2017
U.S. Food and Drug Administration
CMC Considerations for Biotechnology Product Development: A Regulatory Perspective
U.S. Food and Drug Administration
Electronic Common Technical Document (eCTD) and Study Data (7of15) RedI – May 29-30, 2019
U.S. Food and Drug Administration
Putting the Pieces Together: REMS Logic Model in REMS Design, Implementation, and Evaluation
U.S. Food and Drug Administration
FDA | NIH: Regulatory Do’s and Don’ts: Tips from FDA – CBER Segment
U.S. Food and Drug Administration
December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee (PCAC)
U.S. Food and Drug Administration
FDA Clinical Investigator Training Course (CITC) 2024 (Day 1 of 3)
U.S. Food and Drug Administration
Live Demo of the FDA Adverse Events Reporting System (14/14) REdI 2017
U.S. Food and Drug Administration
FDA Clinical Investigator Training Course (CITC) 2024 (Day 3 of 3)
U.S. Food and Drug Administration
FDA Clinical Investigator Training Course (CITC) 2024 (Day 2 of 3)
U.S. Food and Drug Administration